Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world.
Company profile
Ticker
CLB
Exchange
Website
CEO
Lawrence V. Bruno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Core Laboratories Australia PTY LTD • Core Laboratories Canada Ltd. • Core Laboratories International B.V. • Core Laboratories LP • Core Laboratories Malaysia SDN BHD • Core Laboratories Sales B.V. • Core Laboratories (U.K.) Limited • Owen Oil Tools LP • Saybolt Nederland B.V. • Saybolt LP ...
CLB stock data
Latest filings (excl ownership)
15F-12G
Securities registration termination (foreign)
12 May 23
25-NSE
Exchange delisting
2 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 23
Transcripts
CLB
Earnings call transcript
2023 Q4
1 Feb 24
CLB
Earnings call transcript
2023 Q2
27 Jul 23
CLB
Earnings call transcript
2023 Q1
27 Apr 23
CLB
Earnings call transcript
2022 Q4
2 Feb 23
CLB
Earnings call transcript
2022 Q3
27 Oct 22
CLB
Earnings call transcript
2022 Q2
28 Jul 22
CLB
Earnings call transcript
2022 Q1
28 Apr 22
CLB
Earnings call transcript
2021 Q4
3 Feb 22
CLB
Earnings call transcript
2021 Q3
28 Oct 21
CLB
Earnings call transcript
2021 Q2
29 Jul 21
Latest ownership filings
SC 13G/A
ALGER ASSOCIATES INC
12 Jun 23
4
Dijken Eeuwijk Monique van
3 Apr 23
4
Kwaku Temeng
3 Apr 23
4
Michael Straughen
3 Apr 23
4
Katherine Murray
3 Apr 23
4
Harvey Robert Klingensmith
3 Apr 23
4
Martha Z. Carnes
3 Apr 23
4
Mark Damian Tattoli
21 Feb 23
4
Christopher Scott Hill
21 Feb 23
4
Gwendolyn Gresham
21 Feb 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.29 mm | 16.29 mm | 16.29 mm | 16.29 mm | 16.29 mm | 16.29 mm |
Cash burn (monthly) | (no burn) | 479.33 k | (no burn) | (no burn) | 1.06 mm | (no burn) |
Cash used (since last report) | n/a | 6.05 mm | n/a | n/a | 13.34 mm | n/a |
Cash remaining | n/a | 10.23 mm | n/a | n/a | 2.94 mm | n/a |
Runway (months of cash) | n/a | 21.3 | n/a | n/a | 2.8 | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 23 | Carnes Martha Z. | Common Shares | Option exercise | Acquire M | No | No | 0 | 5,485 | 0.00 | 30,592 |
1 Apr 23 | Carnes Martha Z. | Restricted Shares Common Shares | Option exercise | Dispose M | No | No | 0 | 5,485 | 0.00 | 0 |
1 Apr 23 | Carnes Martha Z. | Restricted Shares Common Shares | Grant | Acquire A | No | No | 0 | 6,419 | 0.00 | 6,419 |
1 Apr 23 | Harvey Robert Klingensmith | Common Shares | Option exercise | Acquire M | No | No | 0 | 5,485 | 0.00 | 26,226 |
1 Apr 23 | Harvey Robert Klingensmith | Restricted Shares Common Shares | Option exercise | Dispose M | No | No | 0 | 5,485 | 0.00 | 0 |
1 Apr 23 | Harvey Robert Klingensmith | Restricted Shares Common Shares | Grant | Acquire A | No | No | 0 | 6,419 | 0.00 | 6,419 |
1 Apr 23 | Katherine Murray | Common Shares | Option exercise | Acquire M | No | No | 0 | 5,485 | 0.00 | 5,485 |
1 Apr 23 | Katherine Murray | Restricted Shares Common Shares | Option exercise | Dispose M | No | No | 0 | 5,485 | 0.00 | 0 |
1 Apr 23 | Katherine Murray | Restricted Shares Common Shares | Grant | Acquire A | No | No | 0 | 6,419 | 0.00 | 6,419 |
1 Apr 23 | Straughen Michael | Common Shares | Option exercise | Acquire M | No | No | 0 | 5,485 | 0.00 | 18,991 |
News
Stifel Maintains Hold on Core Laboratories, Lowers Price Target to $17-Report Released on 4 February 2024
5 Feb 24
Core Laboratories Q4 Adj EPS $0.19, Inline, Sales $128.21M Beat $127.77M Estimate
31 Jan 24
Earnings Scheduled For January 31, 2024
31 Jan 24
A Preview Of Core Laboratories's Earnings
30 Jan 24